Christopher Baran, PhD
Primary Care · Columbus, OHNPI 1689082695
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 38.4% of the total.
Across 179 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$396
- Pfizer$396
- GSK$218
- Lilly USA, LLC$132
- Sanofi-aventis U.S. LLC$73
- plus $575 from 19 others
What the payments were for
- Food & beverage$2,908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,118 |
| Novo Nordisk | 32 | $396 |
| Pfizer | 21 | $396 |
| GSK | 14 | $218 |
| Lilly USA, LLC | 7 | $132 |
| Sanofi-aventis U.S. LLC | 3 | $73 |
| Boehringer Ingelheim | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| AstraZeneca | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $44 |
| Abbott | 2 | $41 |
| Boston Scientific | 1 | $41 |
| Novartis | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Dexcom, Inc. | 2 | $29 |
| Bayer | 1 | $28 |
| Mylan Specialty L.p. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Exact Sciences | 1 | $23 |
| Merck | 1 | $20 |
| Amgen | 1 | $17 |
| Corcept Therapeutics | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,908 in reported general payments places this provider in the 85th percentile of 321 primary care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 173 | $146,164 |
| OzempicSemaglutide | 114 | $143,536 |
| JardianceEmpagliflozin | 119 | $93,349 |
| MounjaroTirzepatide | 81 | $91,260 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $85,133 |
| JanuviaSitagliptin Phosphate | 99 | $67,767 |
| FarxigaDapagliflozin Propanediol | 67 | $58,844 |
| TrulicityDulaglutide | 36 | $44,969 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $32,956 |
| RybelsusSemaglutide | 11 | $28,790 |
| XareltoRivaroxaban | 28 | $25,880 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $24,227 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $22,749 |
| MyrbetriqMirabegron | 37 | $21,114 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $15,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $396 | $172,326125 claims |
| PfizerEliquis | $396 | $146,164173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $132 | $136,229117 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $218 | $118,643152 claims |
| Boehringer IngelheimJardiance | $55 | $93,349119 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $48 | $69,70381 claims |
| MerckJanuvia | $20 | $67,76799 claims |
| NovartisEntresto | $30 | $7,98012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 321 primary care providers in Ohio.
Other primary care in Columbus
- Joseph PriceColumbus$6K
- Madison WaltersColumbus$6K
- Jordyn WilsonColumbus$4K
- Macy BaileyColumbus$2K
- Stephanie HoheiselColumbus$2K
- Sheila CaniniColumbus$2K
- Sarah AndersonColumbus$2K
- Shireen ShattiColumbus$2K
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.